Analyst Reco. Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 11:21:02 31/05/2024 am IST			5-day change	1st Jan Change
133.9 ^EUR	-4.76%		0.00%	-11.49%

30/05	Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	MT
29/05	Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	01/05	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	25/04	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	22/04	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	18/04	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	18/04	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	18/04	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	17/04	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	17/04	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	17/04	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	17/04	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	17/04	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	09/04	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	05/04	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	05/04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	24/01	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	24/01	MT
The market awaits the BCE meeting and earnings reports	23/01
The start of a new bull market?	22/01
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	09/01	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	03/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST